<unk> s are drugs that block the action of<unk> s, cellular complexes that break down proteins, like the p53 protein.<unk> s are being studied in the treatment of cancer. In 2003, bortezomib was the first<unk>  to be approved for use in the U.S.
A derivative of epigallocatechin-3-gallate has been proposed as another<unk> .
Proteasome inhibitor
Histone deacetylase inhibitor
COX-2 inhibitor
TNF inhibitor
Antimetabolite
Protein kinase inhibitor
Monoclonal antibodies
Mast cell stabilizer